ОПТИМИЗАЦИЯ МЕДИКАМЕНТОЗНОЙ ТЕРАПИИ БОЛЬНЫХ СТЕНОКАРДИЕЙ – ВАЖНЕЙШАЯ ЗАДАЧА
Номер журнала:
4
Год издания:
2017
Обоснована необходимость оптимизации медикаментозного лечения больных стабильной стенокардией, так как в большинстве случаев медикаментозное лечение не обеспечивает целевого уровня контроля факторов риска плохого прогноза жизни больных и в определенной степени является причиной сохранения показателя смертности от сердечно-сосудистых заболеваний на уровне, который является одним из самых высоких в мире.
Ключевые слова:
кардиология
стабильная стенокардия
статины
дезагреганты
β-адреноблокаторы
антагонисты кальциевых каналов
ивабрадин
нитраты
никорандил
ранолазин
триметазидин
мельдоний
Для цитирования
Мазур Н. ОПТИМИЗАЦИЯ МЕДИКАМЕНТОЗНОЙ ТЕРАПИИ БОЛЬНЫХ СТЕНОКАРДИЕЙ – ВАЖНЕЙШАЯ ЗАДАЧА
. Врач, 2017; (4): 46-52 Список литературы:
- http://www.gks.ru/wps/wcm/connect/rosstatmain/rosstat/ru/statistics/population/ demography
- The Academic Research Organization Consortium for Continuing Evaluation of Scientific Studies – Cardiovascular (ACCESS CV). Sharing Data from Cardiovascular Clinical Trials – A Proposal // N. Engl. J. Med. – 2016; 375: 407–9.
- Саютина Е.В., Чигинева В.В., Золозова Е.А. и др. Контроль ишемии миокарда у больных стенокардией напряжения с многососудистым атеросклеротическим поражением // Кардиология. – 2012; 8: 15–9.
- Карлова Н.А., Золозова Е.А., Пшеницин А.И. и др. Оценка терапевтической эффективности и безопасности оригинального препарата бисопролола и его дженерика бипрола у больных стабильной стенокардией // Кардиология. – 2015; 1: 23–8.
- Euro Heart Survey of stable angina: prospective observational study // Eur. Heart J. – 2005; 26: 1011–22.
- ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults, 2013.
- ESC guidelines stable coronary artery disease // Eur. Heart J. – 2013; 34 (38): 2927–8.
- PEGASUS-TIMI 54 Steering Committee and Investigators. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction // N. Engl. J. Med. – 2015; 372: 1791–800.
- Serebruany V. The TRITON versus PLATO trials: differences beyond platelet inhibition // Thromb. Haemost. – 2010; 103 (2): 259–61.
- CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) // Lancet. – 1996; 348 (9038): 1329–39.
- Lee M., Wu Y., Saver J. et al. Is clopidogrel better than aspirin following breakthrough strokes. A retrospective cohort study // BMJ Open. – 2014; 4 (12): e006672.
- Мазур Н.А. Антиагрегантная терапия у больных ишемической болезнью сердца: нерешенные проблемы // Кардиология. – 2016; 1: 66–70.
- Everly M., Heaton P., Cluxton R. Beta-Blocker Underuse in Secondary Prevention of Myocardial Infarction // Ann. Pharmacother. – 2003; 38: 286–93.
- Le S. Prognostic Significance of Resting Heart Rate and Use of β-Blockers in Atrial Fibrillation and Sinus Rhythm in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Swedish Heart Failure Registry // Circ. Heart Fail. – 2015; 8 (5): 871–9.
- Flather M., Shibata M., Coats A. et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) // Eur. Heart J. – 2005; 26 (3): 215–25.
- Мазур Н.А. Внезапная смерть больных ишемической болезнью сердца / М.: Медицина, 1985; 121–42.
- Hansen J. Treatment with verapamil after an acute myocardial infarction. Review of the Danish studies on verapamil in myocardial infarction (DAVIT I and II) // Drugs. – 1991; 42 (Suppl. 2): 43–53.
- Rehnqvist N., Hjemdahl P., Billing E. et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS) // Eur. Heart J. – 1996; 17 (1): 76–81.
- The Multicenter Diltiazem Postinfarction Trial Research Group The effect of diltiazem on mortality and reinfarction after myocardial infarction // N. Engl. Med. – 1988; 319 (7): 385–92.
- Poole-Wilson P., Lubsen J., Kirwan B. et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial // Lancet. – 2004; 364 (9437): 849–57.
- Мазур Н.А. Практическая кардиология / М.: Медпрактика-М, 2015; 109–37.
- Хоринака Ш. Влияние никорандила на частоту сердечно-сосудистых событий у пациентов с коронарной болезнью сердца // Рос. кардиол. журн. – 2011; 2 (88): 82–90.
- Sakata Y., Nakatani D., Shimizu M. et al. Oral treatment with nicorandil at discharge is associated with reduced mortality after acute myocardial infarction // J. Cardiol. – 2012; 59 (1): 14–21.
- IONA Study Group. Impact of nicorandil in angina: subgroup analyses // Heart. – 2004; 90 (12): 1427–30.
- Stoschitzky K., Rezkalla S., Klone R. Noevidenceof nitrate tolerance with Nicorandil // Eur. Heart J. – 2012; 32 (Abstract Supplement): 470.
- Sekiya M., Sato M., Funada J. et al. Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis // J. Cardiovasc. Pharmacol. – 2005; 46 (1): 63–7.
- Patel D., Purcell H., Fox K. on behalf of the CESAR 2 investigation. Cardioprotection by opening of the KATP channel in unstable angina // Eur. Heart J. – 1999; 20: 51–7.
- Eguchi Y., Takahari Y., Higashijima N. et al. Nicorandil Attenuates FeCl3-Induced Thrombus Formation Through the Inhibition of Reactive Oxygen Species Production // Circ. J. – 2009; 73 (3): 554–61.
- Izumiya Y., Kojima S., Araki S. et al. Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris // Atherosclerosis. – 2011; 214 (2): 415–21.
- Markham A., Plosker G., Goa K. Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardio-protective effects // Drugs. – 2000; 60: 955–74.
- Kasama S., Toyama T., Sumino H. et al. Long-term nicorandil therapy improves cardiac sympathetic nerve activity after reperfusion therapy in patients with first acute myocardial infarction // J. Nucl. Med. – 2007; 48 (10): 1676–82.
- Kasama S., Toyama T., Hatori T. et al. Comparative effects of nicorandil with isosorbide mononitrate on cardiac sympathetic nerve activity and left ventricular function in patients with ischemic cardiomyopathy // Am. Heart J. – 2005; 150 (3): 477.e1–477.e8.
- Evans M., Carrero J., Szummer K. et al. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction // J. Am. Coll. Cardiol. – 2016; 67: 1687–97.
- Sleight P. The HOPE Study (Heart Outcomes Prevention Evaluation) // J. Renin Angiotensin Aldosterone Syst. – 2000; 1 (1): 18–20.
- Campbell D. A review of Perindopril in the reduction of cardiovascular events // Vasc. Health Risk Manag. – 2006; 2 (2): 117–24.
- Tardif J., Ponikowski P., Kahan T. ASSOCIATE Study Investigators. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial // Eur. Heart J. – 2009; 30 (5): 540–8.
- Fox K., Ford I., Steg P. et al. Ivabradine in stable coronary artery disease without clinical heart failure // N. Engl. J. Med. – 2014; 371 (12): 1091–9.
- Tanboğa İ., Topçu S., Aksakal E. et al. The Risk of Atrial Fibrillation With Ivabradine Treatment: A Meta-analysis With Trial Sequential Analysis of More Than 40 000 Patients // Clin. Cardiol. – 2016; 39 (10): 615–20.
- Szwed H., Sadowski Z., Elikowski W. et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand // Eur. Heart J. – 2001; 2 (24): 2267–74.
- The EMIP-FR Group. Effect of 48-h intravenous trimetazidine on short- and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; A double-blind, placebo-controlled, randomized trial European Myocardial Infarction Project – Free Radicals // Eur. Heart J. – 2000; 21 (18): 1537–46.
- www.EMA/412151/2012EMEA/H/A-31/130521 June 2012.
- Chaitman B., Pepine C., Parker J. et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial // JAMA. – 2004; 291 (3): 309–16.
- Melloni C., Newby L. Metabolic efficiency with ranolazineforless ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study // Expert Rev. Cardiovasc. Ther. – 2008; 6 (1): 9–16.
- Стаценко М.Е., Туркина С.В. Метаболическая кардиопротекция мельдонием у больных ишемической болезнью сердца: итоги и перспективы // Лечащий врач. – 2012; 7: 96–103.